title: Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab.
abstract: Infliximab and adalimumab are anti-tumor necrosis factor (TNF) alpha agents used for treating Crohn's disease. Autoimmune hepatitis (AIH) is a rare complication of treatment with these drugs. We report on a case of AIH in a patient with Crohn's disease treated with infliximab who fully recovered after drug withdrawal. More interestingly, because there were no other treatment options, the patient was then treated with adalimumab without recurrence of the liver disease and with control of the intestinal disease.
authors.affiliation: Gastroenterology Department, Instituto Portugus de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal. marilia.cravo@sapo.pt
authors.forename: Marilia
authors.initials: M
authors.lastname: Cravo
authors.forename: Rosa
authors.initials: R
authors.lastname: Silva
authors.forename: Miguel
authors.initials: M
authors.lastname: Serrano
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D019693:Hepatitis, Autoimmune / Q000209:etiology*; D006801:Humans; D000069285:Infliximab; D012008:Recurrence; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab